Aileron Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Rein Therapeutics

09/05/2023 13:00

* Aileron Therapeutics Inc  ALRN.OQ  reported a quarterly
adjusted
loss of $1.05​​ per share for the quarter ended in March. The
lone analyst forecast for the quarter was for a loss of 86 cents
per share.
    * Reported revenue was zero​; analysts expected zero. 
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aileron Therapeutics Inc shares had risen by 19.5% this
quarter and lost 37.5% so far this year.
    * The company reported a quarterly loss of $4.78 million.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.86          -1.05          Missed
 Dec. 31 2022      -1.34          -1.02          Beat
 Sep. 30 2022      -1.65          -1.40          Beat
 Jun. 30 2022      -1.80          -1.80          Met